Next Article in Journal
Impact of Metformin Use on Survival in Patients with Gastric Cancer and Diabetes Mellitus Following Gastrectomy
Next Article in Special Issue
Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2
Previous Article in Journal
Chemosensitivity of Patient-Derived Cancer Stem Cells Identifies Colorectal Cancer Patients with Potential Benefit from FGFR Inhibitor Therapy
Previous Article in Special Issue
Beneficial Molecular Adaptations in BRCA-Mutation Carriers by Combined HIT/HIRT Intervention: Results from a Pilot Study
Review

Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors

1
Institute of Biomedical Research in Malaga (IBIMA), Regional and Virgen de la Victoria University Hospitals Campus de Teatinos s/n, 29010 Málaga, Spain
2
Cancer Molecular Biology Group, Medical Research Center, University of Málaga (UMA), C/Marqués de Beccaría n°3, 29010 Málaga, Spain
3
Medical Oncology Service Intercentros, Regional and Virgen de la Victoria University Hospitals, IBIMA, Campus de Teatinos s/n, 29010 Málaga, Spain
4
Group of Pharmacoepigenetics, Department of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2020, 12(8), 2012; https://doi.org/10.3390/cancers12082012
Received: 20 May 2020 / Revised: 3 July 2020 / Accepted: 20 July 2020 / Published: 22 July 2020
(This article belongs to the Special Issue Molecular Genetics of Breast and Ovary Cancer)
Neoadjuvant Chemotherapy (NAC) in Breast Cancer (BC) has proved useful for the reduction in tumor burden prior to surgery, allowing for a more extensive breast preservation and the eradication of subjacent micrometastases. However, the impact on prognosis is highly dependent on the establishment of Pathological Complete Response (pCR), in particular for Triple Negative (TN) and Hormonal Receptor negative/Human Epidermal growth factor Receptor 2 positive (HR−/HER2+) subtypes. Several pCR predictors, such as PAM50, Integrative Cluster (IntClust), mutations in PI3KCA, or the Trastuzumab Risk model (TRAR), are useful molecular tools for estimating response to treatment and are prognostic. Major evolution events during BC NAC that feature the Residual Disease (RD) are the loss of HR and HER2, which are prognostic of bad outcome, and stemness and immune depletion-related gene expression aberrations. This dynamic nature of the determinants of response to BC NAC, together with the extensive heterogeneity of BC, raises the need to discern the individual and subtype-specific determinants of resistance. Moreover, refining the current approaches for a comprehensive monitoring of tumor evolution during treatment, RD, and eventual recurrences is essential for identifying new actionable alterations and the integral best management of the disease. View Full-Text
Keywords: breast cancer; neoadjuvant chemotherapy; pathological complete response; predictive markers; residual disease breast cancer; neoadjuvant chemotherapy; pathological complete response; predictive markers; residual disease
MDPI and ACS Style

Chica-Parrado, M.R.; Godoy-Ortiz, A.; Jiménez, B.; Ribelles, N.; Barragan, I.; Alba, E. Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. Cancers 2020, 12, 2012. https://doi.org/10.3390/cancers12082012

AMA Style

Chica-Parrado MR, Godoy-Ortiz A, Jiménez B, Ribelles N, Barragan I, Alba E. Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. Cancers. 2020; 12(8):2012. https://doi.org/10.3390/cancers12082012

Chicago/Turabian Style

Chica-Parrado, María R., Ana Godoy-Ortiz, Begoña Jiménez, Nuria Ribelles, Isabel Barragan, and Emilio Alba. 2020. "Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors" Cancers 12, no. 8: 2012. https://doi.org/10.3390/cancers12082012

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop